Engineered t cells
AssigneeIntellia Therapeutics, Inc.
InventorChristopher RUDULIER
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to T cells engineered to comprise a heterologous nucleic acid sequence encoding a dual mutant transforming growth factor beta 1 (dmTGFB1) under control of a promoter sequence. In certain embodiments, the cells further comprise a modification, e.g., knockdown, of an endogenous nucleic acid sequence encoding a TNFA; a modification, e.g., knockdown, of an endogenous nucleic acid sequence encoding an IFNG or an IL17A; and insertion of sequence(s) encoding a regulatory T cell promoting molecule, and compositions and uses thereof.
Claims75
An engineered T cell, comprising:
- a heterologous nucleic acid sequence encoding a dual mutant transforming growth factor beta 1 (dmTGFB1) under control of a promoter sequence.
An engineered T cell, comprising:
- i) a heterologous nucleic acid sequence encoding a regulatory T cell promoting molecule under control of a promoter sequence;
- ii) a modification of an endogenous nucleic acid sequence encoding an interleukin17A (IL17A) wherein the modification knocks down expression of the IL17A;
- and
- iii) a modification of an endogenous a nucleic acid sequence encoding a tumor necrosis factor alpha (TNFA) wherein the modification knocks down expression of TNFA.
A polypeptide comprising a dmTGFB1.
Dependencies are inferred from the claim text.